MANA Advisors LLC bought a new stake in Boston Scientific Co. (NYSE:BSX) in the 4th quarter, according to its most recent filing with the SEC. The fund bought 127,226 shares of the medical equipment provider’s stock, valued at approximately $3,154,000. Boston Scientific accounts for 1.4% of MANA Advisors LLC’s investment portfolio, making the stock its largest holding.
Several other institutional investors and hedge funds have also recently bought and sold shares of BSX. Brown Advisory Inc. grew its holdings in shares of Boston Scientific by 3.0% in the third quarter. Brown Advisory Inc. now owns 60,451 shares of the medical equipment provider’s stock valued at $1,763,000 after purchasing an additional 1,771 shares during the period. Moors & Cabot Inc. lifted its position in shares of Boston Scientific by 3.7% during the third quarter. Moors & Cabot Inc. now owns 49,975 shares of the medical equipment provider’s stock worth $1,468,000 after purchasing an additional 1,800 shares in the last quarter. Private Wealth Partners LLC lifted its position in shares of Boston Scientific by 0.9% during the third quarter. Private Wealth Partners LLC now owns 209,870 shares of the medical equipment provider’s stock worth $6,122,000 after purchasing an additional 1,819 shares in the last quarter. IFM Investors Pty Ltd lifted its position in shares of Boston Scientific by 5.5% during the third quarter. IFM Investors Pty Ltd now owns 39,091 shares of the medical equipment provider’s stock worth $1,140,000 after purchasing an additional 2,038 shares in the last quarter. Finally, Bessemer Group Inc. lifted its position in shares of Boston Scientific by 28.9% during the fourth quarter. Bessemer Group Inc. now owns 10,288 shares of the medical equipment provider’s stock worth $255,000 after purchasing an additional 2,305 shares in the last quarter. Hedge funds and other institutional investors own 91.85% of the company’s stock.
Shares of Boston Scientific Co. (BSX) traded down $0.42 during midday trading on Wednesday, hitting $28.01. The stock had a trading volume of 8,570,000 shares, compared to its average volume of 7,970,000. Boston Scientific Co. has a twelve month low of $24.02 and a twelve month high of $29.93. The stock has a market capitalization of $38,510.00, a P/E ratio of 40.01, a price-to-earnings-growth ratio of 2.06 and a beta of 0.82. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.49 and a current ratio of 0.68.
Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.34. Boston Scientific had a return on equity of 24.27% and a net margin of 1.15%. The firm had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.39 billion. During the same period in the prior year, the business earned $0.30 EPS. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. research analysts anticipate that Boston Scientific Co. will post 1.37 earnings per share for the current fiscal year.
Several brokerages recently weighed in on BSX. Barclays reaffirmed a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a report on Wednesday, January 10th. Needham & Company LLC upgraded shares of Boston Scientific from a “buy” rating to a “strong-buy” rating and raised their target price for the stock from $25.04 to $32.00 in a research report on Friday, December 8th. BMO Capital Markets reiterated a “buy” rating and issued a $31.00 price objective on shares of Boston Scientific in a research report on Wednesday, November 29th. Oppenheimer restated a “hold” rating on shares of Boston Scientific in a research report on Wednesday, November 29th. Finally, Canaccord Genuity decreased their target price on shares of Boston Scientific from $36.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, November 29th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Boston Scientific presently has a consensus rating of “Buy” and a consensus price target of $31.06.
In other news, SVP John Bradley Sorenson sold 1,950 shares of Boston Scientific stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $27.43, for a total transaction of $53,488.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael P. Phalen sold 15,835 shares of the firm’s stock in a transaction that occurred on Friday, December 29th. The stock was sold at an average price of $25.25, for a total value of $399,833.75. The disclosure for this sale can be found here. In the last three months, insiders have sold 174,276 shares of company stock worth $4,592,464. 0.74% of the stock is currently owned by insiders.
Boston Scientific Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.